The transparency discussion is undermined by the fixation on outcomes and the focus on publishing information that realistically adds almost nothing to the community's understanding of how medicines are funded in Australia. This fixation is compounded by a power imbalance that sees all the pressure on the industry when it comes to transparency while 'backroom' processes remain a mysterious locked box.
Transparency of process is more important than transparency of outcome
January 23, 2020 Latest NewsCommentNews of the Day
Latest Video
New Stories
-
First patient successfully dosed in TRP-8803 trial to treat binge eating disorder
December 2, 2025 - - Australian Biotech -
Immutep unveils strong Phase 2 data ahead of San Antonio breast cancer symposium
December 2, 2025 - - Australian Biotech -
US and UK strike landmark pharmaceutical deal, lifting prices
December 2, 2025 - - Latest News -
Cartherics appoints Dr Ian Nisbet as CEO as the company accelerates toward clinical trials
December 1, 2025 - - Australian Biotech -
Novo Nordisk appoints Michael Azrak as new Oceania General Manager
December 1, 2025 - - Latest News -
New PBS listing brings immunotherapy option to Australians with rare head and neck cancer
December 1, 2025 - - Latest News -
DBG Health appoints Matt Zeller to lead Arrotex Pharmaceuticals into its next phase of growth
December 1, 2025 - - Latest News
